First Amendment takes center stage in DTC price fight

A string of court decisions have bolstered commercial speech rights for industry. The Trump administration's push to require prices in TV ads could become the next legal battleground.

By Andrew Dunn • Oct. 22, 2018

Viagra no more: The changing face of drug ads on TV

Gone are twin bathtubs and little blue pills. Instead, pharma promotions on TV are more likely to feature complex biologics and cancer drugs. 

By Ned Pagliarulo • Oct. 22, 2018

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

FDA unconvinced by Novartis pitch for canakinumab

The agency knocked back an application for approval of the drug, already on the market as Ilaris, as a treatment for cardiovascular risk reduction. 

By Jacob Bell • Oct. 19, 2018

AbbVie reaches 5th deal to secure Humira through 2023

Through a settlement with AbbVie, Fresenius Kabi's copycat biologic won't launch in the U.S. until late 2023, pending it securing FDA approval by then. 

By Suzanne Elvidge • Oct. 19, 2018

Amgen launches TV spot for Aimovig in tight CGRP market

The campaign comes days after the Trump administration proposed mandating disclosure of list prices in prescription drug ads.

By Andrew Dunn • Oct. 17, 2018

Minnesota takes aim at Sanofi, Novo, Lilly for insulin prices

A lawsuit filed Tuesday claims that, rather than protect patient access, the companies jacked up insulin prices in order to offer greater rebates to PBMs.

By Jacob Bell • Oct. 17, 2018

Humira biosimilars launch in Europe, testing AbbVie

Copycat biologics of Humira launched on Oct. 16, exposing the world's best-selling drug to competition for the first time since its EU approval in 2003.

By Ned Pagliarulo • Updated Oct. 19, 2018

Amgen, Lilly migraine drugs make it onto Express Scripts' preferred list

The decision boosts Aimovig and Emgality in the competitive CGRP space, while dealing a blow to Teva's rival therapy, Ajovy.

By Jacob Bell • Oct. 17, 2018

Biosimilars bite into Herceptin in Europe

Yet Roche sustained growth thanks to fast uptake of new drugs like Ocrevus. Next year could prove a tougher test, when biosimilars enter in the U.S.

By Ned Pagliarulo • Oct. 17, 2018

An early approval puts Pfizer's Talzenna in a crowded field

Pfizer picked up the PARP inhibitor in its $14 billion deal for Medivation two years ago. Talzenna will join three other drugs on market that work similarly.

By Suzanne Elvidge • Oct. 17, 2018

Engage your HCP audiences through strategic use of digital networks: What's working today

Pharma companies should consider distributing their marketing message through HCP channels.

By Catherine Dold, BioPharma Dive Contributing Editor • Oct. 16, 2018

J&J sees 'evolution in pricing, not a revolution' in 2019

"I think we just need to be careful; things such as list price alone [are] not the full extent of the information," said J&J's pharma unit chief on a Tuesday call.

By Jacob Bell • Oct. 16, 2018

5 questions on the Trump admin's bid to mandate prices in drug ads

Pharma, which spends billions each year to advertise its products on television, is expected to fiercely oppose the proposal.

By Ned Pagliarulo , Andrew Dunn • Oct. 16, 2018

Roche's Kadcyla beats out Herceptin in Phase 3

The data should help to advance the Swiss pharma's plans to reinforce its breast cancer franchise as biosimilar competition to Herceptin creeps in.

By Suzanne Elvidge • Oct. 16, 2018

Confronting pharma, Trump admin seeks price disclosure in drug ads

HHS chief Alex Azar announced the much-anticipated proposal Monday, dismissing a new pledge from trade lobby PhRMA as insufficient.

By Ned Pagliarulo , Andrew Dunn • Updated Oct. 15, 2018

Under pressure, drugmakers give an inch on DTC drug ads

Members of the trade group PhRMA will soon point consumers to drug cost information in direct-to-consumer TV ads, but won't go so far as to include prices upfront.

By Ned Pagliarulo • Updated Oct. 15, 2018

J&J snaps up key label expansion for Xarelto

Regulators cleared the drug to reduce the risk of major cardiovascular events for certain patients, which could help its position against market leading Eliquis.

By Suzanne Elvidge • Oct. 15, 2018

Mylan's generic Copaxone wins in court, but market barriers remain

A court of appeals confirmed Teva's patents for the blockbuster multiple sclerosis drug are invalid, in turn strengthening Mylan's hand.

By Suzanne Elvidge • Oct. 15, 2018

With latest deal, AbbVie keeps another Humira biosimilar at bay

An agreement with Novartis allows for the Swiss pharma's copycat version to launch in the U.S. in September 2023, behind rivals from Amgen and others. 

By Jacob Bell • Oct. 11, 2018

DOJ clears CVS-Aetna union

Approval of the $69 billion deal comes with a condition to sell Aetna's Medicare Part D business. 

By Samantha Liss • Oct. 10, 2018

Price increases on top drugs drove majority of recent growth, analysis finds

Over the past three years, roughly 60% of the growth in U.S. sales for four dozen top-selling drugs came via price increases, according to numbers crunched by investment firm Leerink.

By Ned Pagliarulo • Oct. 10, 2018

Prescription drug spending, prices moderate in Q2

Spending on healthcare services, however, ticked up in the second quarter to post a 4.9% year-over-year growth rate. 

By Les Masterson • Oct. 8, 2018

Approval puts Bausch step closer to dermatology turnaround

It's welcome news for Bausch's struggling dermatology portfolio, which saw the FDA reject another key psoriasis candidate in June.

By Jacob Bell • Oct. 8, 2018

Merck gets a shot in the arm with expanded label for Gardasil

The HPV vaccine is now also approved for adults aged 27 through 45 years old, widening the addressable market for Merck.

By Suzanne Elvidge • Oct. 8, 2018

Gilead reaches deal for Yescarta coverage in England

For now, the CAR-T therapy will be provided through NHS' Cancer Drugs Fund, after a government agency judged it too pricey for routine coverage.

By Ned Pagliarulo • Oct. 5, 2018